BioSpace News Archive

Agilent Technologies Inc. (NYSE: A) will release financial results for the first quarter of fiscal year 2024 after the stock market closes on Tuesday, Feb. 27.

Element Science Receives CE Mark & UKCA Mark for the Jewel® Patch-Wearable Cardioverter Defibrillator.

The U.S. Food and Drug Administration has approved Dupixent® for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with eosinophilic esophagitis.

PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2023 financial results on Thursday, February 15, 2024, at 5:00 pm Eastern Time.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the year ended December 31, 2023 and recent corporate updates, after the closing of the U.S. equity markets on Tuesday, February 27, 2024.

Sagimet Biosciences Inc. announced the pricing of its underwritten public offering of 9,000,000 shares of its Series A common stock at a public offering price of $12.50 per share.

LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, is proud to issue an RFA (Request for Application) for the Career Development Award program.

Panbela Therapeutics, Inc. announced it has reached 50% enrollment for its ASPIRE global clinical trial in the first-line treatment of metastatic pancreatic cancer.

Tonix Pharmaceuticals Holding Corp. today announced a key opinion leader (KOL) webinar to discuss the positive Phase 3 data of TNX-102 SL for the management of fibromyalgia.

Orchard Therapeutics, a global gene therapy leader, today announced the company has reached an agreement with the Beneluxa Initiative on Pharmaceutical Policy (Beneluxa) enabling reimbursed access to Libmeldy ® (atidarsagene autotemcel), a hematopoietic stem cell (HSC) gene therapy, approved for the treatment of early-onset metachromatic leukodystrophy (MLD).